Abbvie Inc. Common Stock (ABBV) 55.79 $ABBV
Is AbbVie's Revised Offer for Shire Finally Enough?
George Budwell, The Motley Fool - Motley Fool - Thu Jul 10, 1:00PM CDT
The biopharma industry has already seen a frenzy of merger and acquisition activity in the first half of 2014. Oddly enough, however, the three largest takeover attempts have all fallen short thus far. Specifically, Pfizer 's various offers for ...
Novartis' Phase III Results on Secukinumab Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 11:00AM CDT
Novartis (NVS) announced that results from two pivotal phase III studies on pipeline candidate, secukinumab (AIN457), were published in the New England Journal of Medicine (NEJM).
Stock Market Today: Markets Pop as Fed Alludes to End of Stimulus
at The Street - Wed Jul 09, 3:58PM CDT
Markets gained ground on Wednesday following the release of Federal Open Market Committee minutes.
Insys Completes Study on Dronabinol Oral Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:55PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has successfully completed a human abuse study on dronabinol oral solution, a liquid formulation of the synthetic cannabinoid dronabinol.
AbbVie Boosts Offer for UK-Based Shire Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:30PM CDT
AbbVie Inc. (ABBV) continues to pursue Shire (SHPG) and has now come up with a fourth proposal.
AbbVie Retracts CEO Claims of Shire Bid Support
at The Street - Wed Jul 09, 12:00PM CDT
AbbVie backed down from a claim underpinning its sweetened $52 billion offer for Irish drugmaker Shire after Takeover Panel intervention.
Stock Market Today: U.S. Stocks Advance Ahead of Fed Minutes; Alcoa Rises
at The Street - Wed Jul 09, 11:10AM CDT
U.S. benchmark stock indices are looking up Wednesday after aluminum giant Alcoa kicked off the second-quarter earnings season with better-than-expected results.
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Why AbbVie (ABBV) Stock Is Slipping This Morning
at The Street - Wed Jul 09, 10:04AM CDT
The drugmaker was forced to retract comments by its CEO about shareholder support for its $51 billion bid for Shire (SHPG) after being caught by British takeover rules.
Drugmakers and Dublin
Chris Hill and Bill Barker, The Motley Fool - Motley Fool - Wed Jul 09, 8:30AM CDT
On Tuesday's Market Foolery, host Chris Hill and Bill Barker, a Motley Fool Funds analyst, jump into the murky waters of AbbVie 's latest bid for Shire . American pharmaceutical firm AbbVie has increased its bid for Shire, a drugmaker based in...
Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 09, 8:15AM CDT
Regado was a big loser last week with the company announcing that an unplanned data review by a Data Safety Monitoring Board (DSMB) is being conducted for a late-stage study on lead pipeline candidate.
Wednesday’s Top Biotech Stories: Celgene, AbbVie, Shire, and Sanofi
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 09, 7:58AM CDT
Let's take a quick look at four stocks -- Celgene , AbbVie , Shire , and Sanofi -- which could all loom large in biotech headlines this Wednesday morning. Celgene's Otezla fails a late-stage trial Celgene has just announced that Otezla,...
Stock Market Today: Stock Futures Rise Ahead of Fed Minutes; Alcoa Advances
at The Street - Wed Jul 09, 7:45AM CDT
Stock futures are ticking higher Wednesday after aluminum giant Alcoa books better-than-expected results. The markets also await the latest Fed minutes.
Ahead of the Bell: Salix Pharma to buy Cosmo Tech
By The Associated Press - AP - Wed Jul 09, 7:37AM CDT
Shares of Salix Pharmaceuticals fell Wednesday before markets opened and a day after it announced plans to become the latest U.S. company to incorporate overseas and lower its taxes.
July 9 Premarket Briefing: 10 Things You Should Know
at The Street - Wed Jul 09, 5:52AM CDT
U.S. stock futures rise slightly ahead of Fed minutes; Citigroup and Justice Department close to a deal; Amazon offers Hachette authors a deal.
European Stocks Slide Ahead of Fed Minutes
at The Street - Wed Jul 09, 4:54AM CDT
Global stock indices on Wednesday extend steep losses from the previous session.
AbbVie raises its bid for Shire
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
The U.S. pharma raised its offer for U.K. drugmaker Shire (SHPG) by 11%, or 22.44 British pounds and 0.8568 AbbVie (ABBV) share for each share of Shire, to more than $51 bil. It's AbbVie's 4th attempt at a buyout after Shire said that the earlier...
If AbbVie Buys Shire, Dividend Investors Should Cheer
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:01PM CDT
AbbVie has made another offer to acquire Shire in a bid to offset looming patent risk and lower its tax rate. Since Shire is generating a significant amount of free cash and currently doesn't pay much in the way of a dividend, acquiring the...
Major Indexes Cut More Losses; Alcoa Turns Up Ahead Of Earnings
at Investor's Business Daily - Tue Jul 08, 1:57PM CDT
Stocks shook off more losses but were still on pace to finish lower for a second straight session. The Nasdaq was off by 1.3%, while the Dow Jones industrial average and the S&P 500 were each off by 0.6%. Turnover continued to track sharply higher on...
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
Is AbbVie's Revised Offer for Shire Finally Enough?
George Budwell, The Motley Fool - Motley Fool - Thu Jul 10, 1:00PM CDT
The biopharma industry has already seen a frenzy of merger and acquisition activity in the first half of 2014. Oddly enough, however, the three largest takeover attempts have all fallen short thus far. Specifically, Pfizer 's various offers for ...
Novartis' Phase III Results on Secukinumab Published - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 10, 11:00AM CDT
Novartis (NVS) announced that results from two pivotal phase III studies on pipeline candidate, secukinumab (AIN457), were published in the New England Journal of Medicine (NEJM).
Stock Market Today: Markets Pop as Fed Alludes to End of Stimulus
at The Street - Wed Jul 09, 3:58PM CDT
Markets gained ground on Wednesday following the release of Federal Open Market Committee minutes.
Insys Completes Study on Dronabinol Oral Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:55PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has successfully completed a human abuse study on dronabinol oral solution, a liquid formulation of the synthetic cannabinoid dronabinol.
AbbVie Boosts Offer for UK-Based Shire Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:30PM CDT
AbbVie Inc. (ABBV) continues to pursue Shire (SHPG) and has now come up with a fourth proposal.
AbbVie Retracts CEO Claims of Shire Bid Support
at The Street - Wed Jul 09, 12:00PM CDT
AbbVie backed down from a claim underpinning its sweetened $52 billion offer for Irish drugmaker Shire after Takeover Panel intervention.
Stock Market Today: U.S. Stocks Advance Ahead of Fed Minutes; Alcoa Rises
at The Street - Wed Jul 09, 11:10AM CDT
U.S. benchmark stock indices are looking up Wednesday after aluminum giant Alcoa kicked off the second-quarter earnings season with better-than-expected results.
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Why AbbVie (ABBV) Stock Is Slipping This Morning
at The Street - Wed Jul 09, 10:04AM CDT
The drugmaker was forced to retract comments by its CEO about shareholder support for its $51 billion bid for Shire (SHPG) after being caught by British takeover rules.
Drugmakers and Dublin
Chris Hill and Bill Barker, The Motley Fool - Motley Fool - Wed Jul 09, 8:30AM CDT
On Tuesday's Market Foolery, host Chris Hill and Bill Barker, a Motley Fool Funds analyst, jump into the murky waters of AbbVie 's latest bid for Shire . American pharmaceutical firm AbbVie has increased its bid for Shire, a drugmaker based in...
Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 09, 8:15AM CDT
Regado was a big loser last week with the company announcing that an unplanned data review by a Data Safety Monitoring Board (DSMB) is being conducted for a late-stage study on lead pipeline candidate.
Wednesday’s Top Biotech Stories: Celgene, AbbVie, Shire, and Sanofi
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 09, 7:58AM CDT
Let's take a quick look at four stocks -- Celgene , AbbVie , Shire , and Sanofi -- which could all loom large in biotech headlines this Wednesday morning. Celgene's Otezla fails a late-stage trial Celgene has just announced that Otezla,...
Stock Market Today: Stock Futures Rise Ahead of Fed Minutes; Alcoa Advances
at The Street - Wed Jul 09, 7:45AM CDT
Stock futures are ticking higher Wednesday after aluminum giant Alcoa books better-than-expected results. The markets also await the latest Fed minutes.
Ahead of the Bell: Salix Pharma to buy Cosmo Tech
By The Associated Press - AP - Wed Jul 09, 7:37AM CDT
Shares of Salix Pharmaceuticals fell Wednesday before markets opened and a day after it announced plans to become the latest U.S. company to incorporate overseas and lower its taxes.
July 9 Premarket Briefing: 10 Things You Should Know
at The Street - Wed Jul 09, 5:52AM CDT
U.S. stock futures rise slightly ahead of Fed minutes; Citigroup and Justice Department close to a deal; Amazon offers Hachette authors a deal.
European Stocks Slide Ahead of Fed Minutes
at The Street - Wed Jul 09, 4:54AM CDT
Global stock indices on Wednesday extend steep losses from the previous session.
AbbVie raises its bid for Shire
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
The U.S. pharma raised its offer for U.K. drugmaker Shire (SHPG) by 11%, or 22.44 British pounds and 0.8568 AbbVie (ABBV) share for each share of Shire, to more than $51 bil. It's AbbVie's 4th attempt at a buyout after Shire said that the earlier...
If AbbVie Buys Shire, Dividend Investors Should Cheer
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:01PM CDT
AbbVie has made another offer to acquire Shire in a bid to offset looming patent risk and lower its tax rate. Since Shire is generating a significant amount of free cash and currently doesn't pay much in the way of a dividend, acquiring the...
Major Indexes Cut More Losses; Alcoa Turns Up Ahead Of Earnings
at Investor's Business Daily - Tue Jul 08, 1:57PM CDT
Stocks shook off more losses but were still on pace to finish lower for a second straight session. The Nasdaq was off by 1.3%, while the Dow Jones industrial average and the S&P 500 were each off by 0.6%. Turnover continued to track sharply higher on...
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
